RMC-6236
Phase 3Small molecule
Revolution MedicinesRMC-6236 is one of 99 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 3.
3
Indications
7
Total Trials
7
Active Trials
98
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1RMC-6236
Revolution MedicinesPhase 3
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
MS Contin
Merck & Co.Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
Active Comparator
ModernaPreclinical
LDE225
NovartisPreclinical
Chemotherapy Agents
TakedaPreclinical
Secretin-Ferring
FerringPreclinical
Concurrent Lenvatinib
TTrans Tasman Radiation Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Ductal Adenocarcinoma1 trial
Patients With Advanced Solid Tumors1 trial
Pancreatic Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RMC-6236. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company